View by Specialty

Trending

DERM1124DesaiQAGraphic01
November 11, 2024
6 min read
Save

Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access

Liver/Biliary Disorders News

SPONSORED CONTENT
Save
SPONSORED CONTENT
July 26, 2024
2 min read
Save

Up to 13% with dementia may instead have ‘treatable’ HE due to undiagnosed cirrhosis

Up to 13% with dementia may instead have ‘treatable’ HE due to undiagnosed cirrhosis

Up to 13% of patients with dementia have lab values that suggest undiagnosed cirrhosis and possible hepatic encephalopathy, an “easily treatable” cause of cognitive impairment, according to a study in The American Journal of Medicine.

SPONSORED CONTENT
July 25, 2024
1 min read
Save

FDA expands Livmarli approval for pruritus in PFIC to infants as young as 12 months

FDA expands Livmarli approval for pruritus in PFIC to infants as young as 12 months

The FDA has updated the label indication for Livmarli for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the patient population to include infants aged 12 months and older.

Trending

DERM1124DesaiQAGraphic01
November 11, 2024
6 min read
Save

Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access

SPONSORED CONTENT
July 25, 2024
2 min read
Save

Up-to-date HCC screening after HCV cure improves survival in patients with cirrhosis

Up-to-date HCC screening after HCV cure improves survival in patients with cirrhosis

Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.

SPONSORED CONTENT
July 24, 2024
3 min read
Save

Risk for heart, liver disease may vary between PCOS subtypes

Risk for heart, liver disease may vary between PCOS subtypes

Women with polycystic ovary syndrome and high androgen levels may have a higher risk for liver disease than those with PCOS and normal androgen levels, according to an analysis of UK Biobank data.

SPONSORED CONTENT
July 22, 2024
2 min read
Save

Fazirsiran lowers serum, liver concentrations of Z-AAT in alpha-1 antitrypsin deficiency

Fazirsiran lowers serum, liver concentrations of Z-AAT in alpha-1 antitrypsin deficiency

In a dose-dependent manner, fazirsiran reduced serum and liver concentrations of Z-AAT and also improved histological measures in patients with homozygous ZZ alpha-1 antitrypsin deficiency-associated liver disease, according to data.

SPONSORED CONTENT
July 17, 2024
2 min read
Save

‘Even one meal change’ to vegetarian, vegan can reduce serum ammonia in cirrhosis

‘Even one meal change’ to vegetarian, vegan can reduce serum ammonia in cirrhosis

Substitution of just one meat-based meal with a vegetarian or vegan alternative reduced serum ammonia levels for up to 3 hours and improved metabolites in patients with cirrhosis who follow a Western meat-based diet, researchers reported.

SPONSORED CONTENT
July 15, 2024
2 min watch
Save

VIDEO: GLP-1 use for MASH is ‘not black and white’; best approach may lie in the gray

VIDEO: GLP-1 use for MASH is ‘not black and white’; best approach may lie in the gray

In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that, despite the boom in glucagon-like peptide-1 agonists for diabetes and weight loss, its role in the treatment of liver disease is still up for debate.

SPONSORED CONTENT
July 15, 2024
3 min read
Save

‘Highly plausible’ GLP-1s can improve health-related QoL, economic burden of MASH

‘Highly plausible’ GLP-1s can improve health-related QoL, economic burden of MASH

Metabolic dysfunction-associated steatotic liver disease affects more than one-third of the world’s population and is associated with significant clinical and economic burden, as well as impairment of health-related quality of life.

SPONSORED CONTENT
July 15, 2024
3 min read
Save

‘Whether or not we like it,’ GLP-1s are part of hepatology, treatment of MASH

‘Whether or not we like it,’ GLP-1s are part of hepatology, treatment of MASH

To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.

SPONSORED CONTENT
July 15, 2024
3 min read
Save

More data needed on GLP-1s, dual agonists to reach ‘optimal’ management of MASH, diabetes

More data needed on GLP-1s, dual agonists to reach ‘optimal’ management of MASH, diabetes

Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails